ABSTRACT -The authors describe the case of a young Brazilian woman who was treated of ileocolonic
INTRODUCTION
Crohn's disease (CD) and systemic lupus erythematosus (SLE) have been described in a rare association (3) . Both disease have ethiopathogenesis not well known, but the more accepted theory for explanation is based in the interaction of environmental agents and immunological responses in a host genetically susceptible (4) . Sometimes the differentiation of intestinal lesions of CD from SLE is not easy. Gastrointestinal symptoms, laboratory studies, and radiographic findings may appear very similar in both diseases. However, the association of both diseases in a same patient it is not common. We report a patient, who developed a SLE with fatal evolution after 7 years of treatment for ileocolonic CD.
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CASE REPORT
A 24-year old Brazilian woman presented, in March 1992, with diarrhea, weight loss and abdominal pain. She had perineal and vaginal fistulae. A colonoscopy showed longitudinal scattered ulcers and erosions from ileum to descending colon. The hystopathological examination of samples of ileum and colonic mucosa demonstrated cryptitis and noncaseating granulomas. She was considered to have CD and sulfasalazine 3 g/day plus metronidazol 15 mg/kg/day were started. A clinical remission was achieved with healing of fistulae, gain of weight and relief of abdominal pain. After 6 months only sulfasalazine was being employed. She felt well for 4 years. In April 1996 she developed a "lupus-like syndrome", with skin facial lesions in "vespertilio", arthralgias and fever. High titers of autoimmune antibodies (anti-ANA) and LE cells were demonstrated in laboratory researches. She was considered to have a sulfasalazineinduced lupus syndrome and mesalazine 1.6 g/day was introduced in treatment after sulfasalazine withdrawal. A complete remission of all clinical and laboratory manifestations was observed and the patient became well for the next 3 years. She was admitted again in February 1999, with perineal fistula, fever (39 ºC), arthralgias, weakness, strabismus, and hipoaestesia in the feet and both hands. The laboratory tests showed hypocomplementemia, and high titers of anti-ANA (1:320) and anti-Ro (SS-A) antibody positive, while the anti-histone antibody was negative. Urinalysis demonstrated proteinuria, microhaematuria and haematic casts. The hipoaestesia progressed to anesthesia and paraparesia of upper and lower limbs. The study of cranium and medullae through a CT scan and a MNR did not show any abnormalities. The liquor was clear with a normal protein concentration and cell count, and negative bacterioscopy analysis and culture. The above findings are in according with the American College of Rheumathology criteria for the diagnosis of SLE (10) . A pulsotherapy with methylprednisolone was started. No signs of improvement were noticed and a cyclophosphamide trial was tried without any response. She became tetraplegic. A severe respiratory failure occurred in the 8th day and an assisted ventilatory support was introduced. No improvement was observed and she died on the 15th day.
DISCUSSION
SLE is a multisystemic autoimmune disease with protean clinical presentations as a result of widespread inflammation and immune complex deposition. During evolution of SLE, gastrointestinal symptoms occur in approximately 50% of patients (5) . Virtually any gastrointestinal tissue can be involved, most often as a result of SLE vasculopathy.
Although it remains unclear whether CD is autoimmune in nature, perinuclear staining antineuthrophil cytoplasmic antibodies (p-ANCA), known to be associated with vasculitis and tissue injury by activating leukocytes, occur near 15% of the cases, while remission of the disease, in the presence of HIV-infection and exacerbation, after treatment with interleukin-2, have been reported (6, 9) . Several case reports have indicated that differentiation of CD from SLE may be difficult. Gastrointestinal symptoms, laboratory studies, and radiographic findings may have similar features in both diseases (1) . Moreover, the SLE syndrome has been described in patients with CD after sulfasalazine (2) as well as mesalazine treatment (11) . Curiously, acute leukocytoclastic vasculitis of skin has been described in CD with the same characteristics of autoimmune diseases (12) . However, coexistence of SLE and CD has been rarely described (3, 7, 8) .
In all these clinical situations the correct diagnosis has important treatment and prognostic implications. In our case, the biopsy specimens from the ileal and colonic mucosa showed cryptitis and non-caseating granuloma with no ischemic changes or vasculitis. After 7-years of well-controlled CD with medical treatment, the patient developed complex systemic manifestations, with hypocomplementemia, high titers of anti-ANA and anti-Ro (SS-A) antibody positive. Proteinuria, microhaematuria and haematic casts were found in urinalysis. These findings are in according with SLE diagnosis. The anti-histone antibody negative makes the hypothesis of drug-induced lupus syndrome improbable (11) . Based on these facts, we believe that our patient could accurately be diagnosed as having idiophatic SLE with CD.
In conclusion, although some of the systemic complications of these diseases may overlap, both diseases may occur as primary disorders. Coexistence of SLE in patients with inflammatory bowel diseases, should be considered when complex extraintestinal manifestations are present, especially when autoimmune-antibodies are detected.
